Two cases of nintedanib-induced diarrhoea treated using a 5-hydroxytryptamine type 3 receptor antagonist.

Published in: ERJ open research (2022)

Nintedanib-induced diarrhoea may be controlled by ramosetron by modulation of intestinal motility as for irritable bowel syndrome #pulmonaryfibrosis https://bit.ly/3OQVAII.

Keyphrases

irritable bowel syndrome
high glucose
idiopathic pulmonary fibrosis
diabetic rats
drug induced
oxidative stress
endothelial cells
escherichia coli
cystic fibrosis